Cardiac Aggressive Risk Mitigation in Thoracic Radiotherapy (CARMA) Trial
The purpose of this study is to examine adherence to cardio-oncology consultation.
Checked against the public recordLast updated Feb 6, 2025 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Supportive Care
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Cedars-Sinai Medical Center
- Interventions being studied
- Other: Cardiac Aggressive Risk MitigAtion Plan
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Any stage (I-IV) malignancy being treated with high dose (≥30 Gy) radiotherapy where the heart is in the treatment field. * Have Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2. * Planning to receive standard of care radiotherapy treatments. * Access to a smart device that has the capability to sync to the devices. * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. * Ability to read, write and understand English. Exclusion Criteria: * Known allergy to surgical steel or elastomer/rubber. * Heart attack within 6 months prior to study enrollment. * Severe and/or active scleroderma or systemic lupus erythematosus.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Cancer Clinical Trials OfficeLos Angeles, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 6, 2025. Always confirm current availability with the study team.